ArticleScientific reports2022
Multi-centre discriminating concentration determination of broflanilide and potential for cross-resistance to other public health insecticides in Anopheles vector populations.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- A noninferiority cluster randomised evaluation of a broflanilide indoor residual spraying insecticide, VECTRON T500, for malaria vector control in Tanzania.Scientific reports · 2025Trial
- Long-lasting residual efficacy of a new indoor residual spraying product, VECTRONParasites & vectors · 2024Trial
- Community evaluation of VECTRON™ T500, a broflanilide insecticide, for indoor residual spraying for malaria vector control in central Benin; a two arm non-inferiority cluster randomised trial.Scientific reports · 2023Trial
- Small molecules as arthropod kinin receptor antagonists, feeding modulators, or novel mosquitocidal agents.Pest management science · 2026Article
- Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.Malaria journal · 2026Article
- Multi-omics insights into mosquito insecticide resistance for integrated vector management.PeerJ · 2026Review
- Community evaluation of VECTRON™ T500 (broflanilide) for indoor residual spraying for malaria vector control in Siaya county, Kenya.Malaria journal · 2025Article
- Susceptibility of the invasive malaria vector Anopheles stephensi in Ethiopia to novel chemical insecticides and insect growth regulator.Scientific reports · 2025Article
- Determination of the residual efficacy of broflanilide (VECTRON™ T500) insecticide for indoor residual spraying in a semi-field setting in Ethiopia.Malaria journal · 2025Article
- Insecticide susceptibility status of Anopheles stephensi against novel insecticides in Eastern Ethiopia.Research square · 2024Article
- Article
- Anopheles gambiae larvae's ability to grow and emerge in water containing lethal concentrations of clothianidin, acetamiprid, or imidacloprid is consistent with cross-resistance to neonicotinoids.Parasites & vectors · 2024Article
- Clothianidin-resistant Anopheles gambiae adult mosquitoes from Yaoundé, Cameroon, display reduced susceptibility to SumiShield® 50WG, a neonicotinoid formulation for indoor residual spraying.BMC infectious diseases · 2024Article
- Vegetable oil-based surfactants are adjuvants that enhance the efficacy of neonicotinoid insecticides and can bias susceptibility testing in adult mosquitoes.PLoS neglected tropical diseases · 2023Article
- Resistance to clothianidin reduces the efficacy of SumiShieldResearch square · 2023Article
- Identification of two insecticide resistance markers in Ethiopian Anopheles stephensi mosquitoes using a multiplex amplicon sequencing assay.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
Novel insecticides are urgently needed to control insecticide-resistant populations of Anopheles malaria vectors. Broflanilide acts as a non-competitive antagonist of the gamma-aminobutyric acid receptor and has shown prolonged effectiveness as an indoor residual spraying product (VECTRON T500) in experimental hut trials against pyrethroid-resistant vector populations. This multi-centre study expanded upon initial discriminating concentration testing of broflanilide, using six Anopheles insectary colonies (An. gambiae Kisumu KCMUCo, An. gambiae Kisumu NIMR, An. arabiensis KGB, An. arabiensis SENN, An. coluzzii N'Gousso and An. stephensi SK), representing major malaria vector species, to facilitate prospective susceptibility monitoring of this new insecticide; and investigated the potential for cross-resistance to broflanilide via the A296S mutation associated with dieldrin resistance (rdl). Across all vector species tested, the discriminating concentration for broflanilide ranged between LC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.